Core Viewpoint - RadNet, Inc. has completed the acquisition of iCAD, Inc., enhancing its capabilities in AI-powered breast health solutions and advancing its mission in diagnostic imaging and digital health [1][2][6] Company Overview - RadNet is a leading provider of diagnostic imaging services in the U.S., operating 401 outpatient imaging centers and employing over 11,000 staff [4] - DeepHealth, a subsidiary of RadNet, focuses on AI-powered health informatics to improve clinical outcomes in various health areas, including breast health [5] Acquisition Details - The acquisition integrates iCAD's commercial, technology, and regulatory capabilities into DeepHealth, aiming to improve breast cancer detection and screening programs [2][6] - iCAD's AI portfolio is deployed in over 50 countries and includes solutions for breast cancer detection, risk evaluation, and workflow efficiency [2][3] Market Impact - The acquisition allows DeepHealth to access over 1,500 healthcare provider locations globally, enabling the delivery of more than 10 million mammograms annually [3] - This strategic move is expected to accelerate AI adoption and enhance screening compliance, particularly in underserved communities [3][6]
RadNet’s Wholly-Owned Subsidiary, DeepHealth, Completes Acquisition of iCAD